Trial Profile
Phase II Trial of Cetuximab in Combination With Chemotherapy (Carboplatin and Navelbine) for Patients With Platinum-resistant Head and Neck Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2020
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Carboplatin; Vinorelbine
- Indications Head and neck cancer
- Focus Biomarker; Therapeutic Use
- Acronyms CCV-NKU; CECAVI
- 29 Oct 2020 Planned End Date changed from 1 Dec 2012 to 1 Jan 2012.
- 29 Oct 2020 Status changed from completed to withdrawn prior to enrolment.
- 13 Oct 2012 Status changed from recruiting to completed as reported by EudraCT.